On Monday, Abbvie Inc (NYSE: ABBV) opened lower -0.38% from the last session, before settling in for the closing price of $162.28. Price fluctuations for ABBV have ranged from $130.96 to $182.89 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 11.76% annually for the last half of the decade. Company’s average yearly earnings per share was noted 0.34% at the time writing. With a float of $1.77 billion, this company’s outstanding shares have now reached $1.77 billion.
In an organization with 50000 employees, it is important to assess its efficiency.
Abbvie Inc (ABBV) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Abbvie Inc is 0.11%, while institutional ownership is 71.77%. The most recent insider transaction that took place on Mar 20 ’24, was worth 3,716,757. In this transaction EVP, CHIEF BUS/STRAT OFFICER of this company sold 21,082 shares at a rate of $176.30, taking the stock ownership to the 55,903 shares. Before that another transaction happened on Mar 18 ’24, when Company’s EVP, CHIEF COMMERCIAL OFFICER sold 58,949 for $178.79, making the entire transaction worth $10,539,508. This insider now owns 60,941 shares in total.
Abbvie Inc (ABBV) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.28% during the next five years compared to -5.77% drop over the previous five years of trading.
Abbvie Inc (NYSE: ABBV) Trading Performance Indicators
Check out the current performance indicators for Abbvie Inc (ABBV). In the past quarter, the stock posted a quick ratio of 0.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.27. Likewise, its price to free cash flow for the trailing twelve months is 13.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.72, a number that is poised to hit 2.28 in the next quarter and is forecasted to reach 12.17 in one year’s time.
Technical Analysis of Abbvie Inc (ABBV)
Let’s dig in a bit further. During the last 5-days, its volume was 4.99 million. That was inferior than the volume of 5.68 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 6.76%. Additionally, its Average True Range was 3.49.
During the past 100 days, Abbvie Inc’s (ABBV) raw stochastic average was set at 53.62%, which indicates a significant increase from 7.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.95% in the past 14 days, which was higher than the 17.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $175.85, while its 200-day Moving Average is $155.46. However, in the short run, Abbvie Inc’s stock first resistance to watch stands at $163.75. Second resistance stands at $165.82. The third major resistance level sits at $166.95. If the price goes on to break the first support level at $160.55, it is likely to go to the next support level at $159.42. Assuming the price breaks the second support level, the third support level stands at $157.35.
Abbvie Inc (NYSE: ABBV) Key Stats
There are currently 1,770,647K shares outstanding in the company with a market cap of 286.26 billion. Presently, the company’s annual sales total 54,318 M according to its annual income of 4,863 M. Last quarter, the company’s sales amounted to 14,301 M and its income totaled 822,000 K.
